Thomas Jefferson University

Stephen Silberstein

TitleProfessor
InstitutionThomas Jefferson University
DepartmentNeurology
Address111 S. 11th Street
Philadelphia PA 19107
Phone215-955-2243
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Headache guidelines

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Pozo-Rosich P, Alpuente A, Silberstein SD, Burstein R. Insights from 25?years of onabotulinumtoxinA in migraine - mechanisms and management. Nat Rev Neurol. 2024 09; 20(9):555-568. PMID: 39160284.
      Citations:    
    2. Vives-Mestres M, Casanova A, Silberstein SD, Hershey AD, Orr SL. Clinical factors associated with day-to-day peak pain severity in individuals with chronic migraine: A cohort study using daily prospective diary data. Headache. 2024 Jun 27. PMID: 38932610.
      Citations:    
    3. Silberstein SD, Diener HC, Dodick DW, Sommer K, Lipton RB. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials. Headache. 2024 Jul-Aug; 64(7):838-848. PMID: 38982666.
      Citations:    
    4. Alabbad S, Figueredo N, Yuan H, Silberstein S. Developments in targeting calcitonin gene-related peptide. Expert Rev Neurother. 2024 Apr 01; 1-9. PMID: 38557226.
      Citations:    
    5. Yuan H, Silberstein SD. How early can we treat migraine attacks? A perspective based on prodrome. Med. 2024 Mar 08; 5(3):179-180. PMID: 38460496.
      Citations:    
    6. Duncan CW, Silberstein SD. Evidence-based preventive treatment of migraine. Handb Clin Neurol. 2024; 199:219-241. PMID: 38307648.
      Citations:    
    7. Fishman MA, Chitneni A, Abd-Elsayed A, Grodofsky S, Scherer AM, Schetzner B, Klusek M, Popielarski SR, Meloni S, Falowski S, Kim P, Slavin KV, Silberstein SD. Drug-Free Noninvasive Thermal Nerve Block: Validation of Sham Devices. Brain Sci. 2023 Dec 15; 13(12). PMID: 38137166.
      Citations:    
    8. Fiorella D, Arthur AS, Yuan H, Bhogal P, Goyal N, Khattar NK, Albuquerque FC, Jadhav AP, Catapano JS, Silberstein S. Refractory migraine: a cerebrovascular disease? J Neurointerv Surg. 2023 Nov 08. PMID: 37940385.
      Citations:    
    9. Wang VS, Kosman J, Yuan H, Lauritsen C, Shrewsbury S, Aurora SK, Hopkins M, Silberstein S. Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study. Headache. 2023 Sep 23. PMID: 37740562.
      Citations:    
    10. Berk T, Silberstein S, McAllister P. A Novel Virtual-Based Comprehensive Clinical Approach to Headache Care. J Clin Med. 2023 Aug 17; 12(16). PMID: 37629391.
      Citations:    
    11. Blumenfeld AM, Lipton RB, Silberstein S, Tepper SJ, Charleston L, Landy S, Kuruvilla DE, Manack Adams A. Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review. Neurol Ther. 2023 Oct; 12(5):1533-1551. PMID: 37542624.
      Citations:    
    12. Turkel CC, Aurora S, Diener HC, Dodick DW, Lipton RB, Silberstein SD, Brin MF. Treatment of chronic migraine with Botox (onabotulinumtoxinA): Development, insights, and impact. Medicine (Baltimore). 2023 Jul 01; 102(S1):e32600. PMID: 37499085.
      Citations:    
    13. Silberstein S, Spierings ELH, Kunkel T. Celecoxib Oral Solution and the Benefits of Self-Microemulsifying Drug Delivery Systems (SMEDDS) Technology: A Narrative Review. Pain Ther. 2023 Jun 17. PMID: 37329440.
      Citations:    
    14. Tepper SJ, Lipton RB, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Wang A, Cheng S, Klatt J, Mikol DD. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis. Headache. 2023 Jun; 63(6):730-742. PMID: 37313616.
      Citations:    
    15. Ceriani CEJ, Silberstein SD. Current and emerging pharmacotherapy for menstrual migraine: a narrative review. Expert Opin Pharmacother. 2023 Mar 23; 1-11. PMID: 36946205.
      Citations:    
    16. Silberstein SD, Reshef S, Cohen JM, Gandhi S, Seminerio M, Ramirez Campos V, Kessler Y, Thompson SF, Blumenfeld A. Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System. Adv Ther. 2023 Feb; 40(2):445-459. PMID: 36350532.
      Citations:    
    17. Schwenk ES, Walter A, Torjman MC, Mukhtar S, Patel HT, Nardone B, Sun G, Thota B, Lauritsen CG, Silberstein SD. Lidocaine infusions for refractory chronic migraine: a retrospective analysis. Reg Anesth Pain Med. 2022 Jul; 47(7):408-413. PMID: 35609890.
      Citations:    
    18. Schwedt TJ, Tassorelli C, Silberstein SD, Szperka CL, Kurth T, Pozo-Rosich P, Amin FM, Lipton RB, Dodick DW, Ashina M, Diener HC, Terwindt GM. Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1st edition. Cephalalgia. 2022 May 06; 3331024221099035. PMID: 35514209.
      Citations:    
    19. Cohen F, Yuan H, Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale. BioDrugs. 2022 May; 36(3):341-358. PMID: 35476215.
      Citations:    
    20. Borlak J, Diener HC, Kleeberg-Hartmann J, Messlinger K, Silberstein S. Petasites for Migraine Prevention: New Data on Mode of Action, Pharmacology and Safety. A Narrative Review. Front Neurol. 2022; 13:864689. PMID: 35585841.
      Citations:    
    21. Cohen F, Yuan H, DePoy EMG, Silberstein SD. The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine. Neurotherapeutics. 2022 Apr 14. PMID: 35426060.
      Citations:    
    22. Diener HC, McAllister P, Jürgens TP, Kessler Y, Ning X, Cohen JM, Campos VR, Barash S, Silberstein SD. Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. Cephalalgia. 2022 Mar 25; 3331024221076485. PMID: 35331009.
      Citations:    
    23. Lampl C, Rapoport AM, Cohen JM, Barash S, Ramirez Campos V, Seminerio MJ, Ning X, Silberstein SD. Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction. Eur J Neurol. 2022 Mar 18. PMID: 35302681.
      Citations:    
    24. Yuan H, Curran JG, Keith SW, Hopkins MM, Silberstein SD. Intravenous ibuprofen for acute treatment of migraine: A double-blind, randomized, placebo-controlled pilot study. Headache. 2021 Oct; 61(9):1432-1440. PMID: 34601736.
      Citations:    
    25. Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2021 Sep 14; 3331024211042385. PMID: 34521260.
      Citations:    
    26. Schwenk ES, Torjman MC, Moaddel R, Lovett J, Katz D, Denk W, Lauritsen C, Silberstein SD, Wainer IW. Ketamine for Refractory Chronic Migraine: An Observational Pilot Study and Metabolite Analysis. J Clin Pharmacol. 2021 Nov; 61(11):1421-1429. PMID: 34125442.
      Citations:    
    27. Bharadwaj VN, Porreca F, Cowan RP, Kori S, Silberstein SD, Yeomans DC. A new hypothesis linking oxytocin to menstrual migraine. Headache. 2021 Jul; 61(7):1051-1059. PMID: 34125955.
      Citations:    
    28. Ishii R, Schwedt TJ, Dumkrieger G, Lalvani N, Craven A, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD, Burish MJ, Dodick DW. Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache. 2021 Jul; 61(7):992-1003. PMID: 34081791.
      Citations:    
    29. Tassorelli C, Diener HC, Silberstein SD, Dodick DW, Goadsby PJ, Jensen RH, Magis D, Pozo-Rosich P, Yuan H, Martinelli D, Hoek TVD, Deen M, Ashina M, Terwindt GM. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. Cephalalgia. 2021 Oct; 41(11-12):1135-1151. PMID: 33990161.
      Citations:    
    30. Hutchinson S, Silberstein SD, Blumenfeld AM, Lipton RB, Lu K, Yu SY, Severt L. Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II. Cephalalgia. 2021 Apr 19; 3331024211000311. PMID: 33874756.
      Citations:    
    31. Mojadidi MK, Kumar P, Mahmoud AN, Elgendy IY, Shapiro H, West B, Charles AC, Mattle HP, Sorensen S, Meier B, Silberstein SD, Tobis JM. Pooled Analysis of PFO Occluder Device Trials in Patients With PFO and Migraine. J Am Coll Cardiol. 2021 Feb 16; 77(6):667-676. PMID: 33573735.
      Citations:    
    32. Pavlovic JM, Yu JS, Silberstein SD, Reed ML, Cowan RP, Dabbous F, Pulicharam R, Viswanathan HN, Lipton RB. Evaluation of the 6-item Identify Chronic Migraine screener in a large medical group. Headache. 2021 Jan 09. PMID: 33421098.
      Citations:    
    33. Silberstein SD, Cohen JM, Yang R, Gandhi SK, Du E, Jann AE, Marmura MJ. Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials. J Headache Pain. 2021 Jan 07; 22(1):2. PMID: 33413075.
      Citations:    
    34. Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F, Zhang F, Paiva da Silva Lima G, Cheng S, Mikol DD. Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol. 2021 Jan 05. PMID: 33400330.
      Citations:    
    35. Yuan H, Silberstein SD. Correction to: The Use of Botulinum Toxin in the Management of Headache Disorders. Handb Exp Pharmacol. 2021; 263:289. PMID: 33315150.
      Citations:    
    36. Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Zhang F, Rippon GA, Cheng S, Mikol DD. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia. 2021 Jan; 41(1):6-16. PMID: 33269951.
      Citations:    
    37. Blumenfeld AM, Silberstein SD. Response to "Modifications to the PREEMPT Protocol for OnabotulinumtoxinA Injections for Chronic Migraine in Clinical Practice". Headache. 2020 Nov; 60(10):2597-2599. PMID: 33107587.
      Citations:    
    38. Diener HC, Dodick DW, Lipton RB, Manack Adams A, DeGryse RE, Silberstein SD. Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis. Pain Ther. 2020 Dec; 9(2):683-694. PMID: 33026631.
      Citations:    
    39. Silberstein SD, Diener HC, Dodick DW, Manack Adams A, DeGryse RE, Lipton RB. The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine. Pain Ther. 2020 Dec; 9(2):695-707. PMID: 33026630.
      Citations:    
    40. Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24?weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain. 2020 Oct 06; 21(1):120. PMID: 33023473.
      Citations:    
    41. Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z. The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain. 2020 Sep 21; 21(1):114. PMID: 32958075.
      Citations:    
    42. Ceriani CE, Silberstein SD. Headache and rhinosinusitis: A review. Cephalalgia. 2020 Sep 20; 333102420959790. PMID: 32954817.
      Citations:    
    43. Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, Dodick DW. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology. 2020 11 03; 95(18):e2487-e2499. PMID: 32913018.
      Citations:    
    44. Parikh SK, Delbono MV, Silberstein SD. Managing migraine in pregnancy and breastfeeding. Prog Brain Res. 2020; 255:275-309. PMID: 33008509.
      Citations:    
    45. Silberstein SD, Yuan H, Najib U, Ailani J, Morais AL, Mathew PG, Liebler E, Tassorelli C, Diener HC. Non-invasive vagus nerve stimulation for primary headache: A clinical update. Cephalalgia. 2020 Jul 27; 333102420941864. PMID: 32718243.
      Citations:    
    46. Burstein R, Blumenfeld AM, Silberstein SD, Manack Adams A, Brin MF. Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review. Headache. 2020 Jun 30. PMID: 32602955.
      Citations:    
    47. Yuan H, Silberstein SD. The Use of Botulinum Toxin in the Management of Headache Disorders. Handb Exp Pharmacol. 2020 Jun 20. PMID: 32562057.
      Citations:    
    48. Marcus SC, Shewale AR, Silberstein SD, Lipton RB, Young WB, Viswanathan HN, Doshi JA. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response. Cephalalgia. 2020 Mar 29; 333102420915167. PMID: 32223301.
      Citations:    
    49. Tepper SJ, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein SD, Winner P, Zhang F, Cheng S, Mikol DD. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study. Cephalalgia. 2020 Mar 26; 333102420912726. PMID: 32216456.
      Citations:    
    50. Parikh SK, Burkett JG, Silberstein SD. A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine. Expert Opin Drug Saf. 2020 Mar 09; 1-7. PMID: 32116061.
      Citations:    
    51. Bonafede M, McMorrow D, Noxon V, Desai P, Sapra S, Silberstein S. Care Among Migraine Patients in a Commercially Insured Population. Neurol Ther. 2020 Feb 15. PMID: 32062840.
      Citations:    
    52. Alpuente A, Tassorelli C, Diener HC, Silberstein SD, Pozo-Rosich P. Have the IHS Guidelines for controlled trials of acute treatment of migraine attacks been followed? Laying the ground for the 4th edition. Cephalalgia. 2020 Feb 14; 333102420906843. PMID: 32056459.
      Citations:    
    53. Dodick DW, Shewale AS, Lipton RB, Baum SJ, Marcus SC, Silberstein SD, Pavlovic JM, Bennett NL, Young WB, Viswanathan HN, Doshi JA, Weintraub H. Migraine Patients With Cardiovascular Disease and Contraindications: An Analysis of Real-World Claims Data. J Prim Care Community Health. 2020 Jan-Dec; 11:2150132720963680. PMID: 33095099.
      Citations:    
    54. Evans RW, Burch RC, Frishberg BM, Marmura MJ, Mechtler LL, Silberstein SD, Turner DP. Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline. Headache. 2019 Dec 31. PMID: 31891197.
      Citations:    
    55. Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC. Correction to: Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain. 2019 12 27; 20(1):118. PMID: 31881817.
      Citations:    
    56. Tepper SJ, Silberstein SD, Rosen NL, Lipton RB, Dennehy EB, Dowsett SA, Doty E. The Influence of Migraine on Driving: Current Understanding, Future Directions, and Potential Implications of Findings. Headache. 2020 Jan; 60(1):178-189. PMID: 31792964.
      Citations:    
    57. Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) - Then and Now: A Narrative Review. Headache. 2020 Jan; 60(1):40-57. PMID: 31737909.
      Citations:    
    58. Ashina M, Kudrow D, Reuter U, Dolezil D, Silberstein S, Tepper SJ, Xue F, Picard H, Zhang F, Wang A, Zhou Y, Hong F, Klatt J, Mikol DD. Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions. Cephalalgia. 2019 Dec; 39(14):1798-1808. PMID: 31707815.
      Citations:    
    59. Rothrock JF, Adams AM, Lipton RB, Silberstein SD, Jo E, Zhao X, Blumenfeld AM. FORWARD Study: Evaluating the Comparative Effectiveness of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine. Headache. 2019 Sep 26. PMID: 31559634.
      Citations:    
    60. Ceriani CEJ, Wilhour DA, Silberstein SD. Novel Medications for the Treatment of Migraine. Headache. 2019 Sep 26. PMID: 31559638.
      Citations:    
    61. Parikh SK, Silberstein SD. Preventive Treatment for Episodic Migraine. Neurol Clin. 2019 Nov; 37(4):753-770. PMID: 31563231.
      Citations:    
    62. Silberstein SD, Cohen JM, Yeung PP. Fremanezumab for the preventive treatment of migraine. Expert Opin Biol Ther. 2019 Aug; 19(8):763-771. PMID: 31177856.
      Citations:    
    63. Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. Headache. 2019 Jul; 59 Suppl 2:20-32. PMID: 31291020.
      Citations:    
    64. Silberstein SD, Stauffer VL, Day KA, Lipsius S, Wilson MC. Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). J Headache Pain. 2019 Jun 28; 20(1):75. PMID: 31253091.
      Citations:    
    65. Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J, Cady R, Smith J. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019 Aug; 39(9):1075-1085. PMID: 31234642.
      Citations:    
    66. de Coo IF, Marin JC, Silberstein SD, Friedman DI, Gaul C, McClure CK, Tyagi A, Liebler E, Tepper SJ, Ferrari MD, Goadsby PJ. Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis. Cephalalgia. 2019 Jul; 39(8):967-977. PMID: 31246132.
      Citations:    
    67. Diener HC, Dodick D, Evers S, Holle D, Jensen RH, Lipton RB, Porreca F, Silberstein S, Schwedt T. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019 Sep; 18(9):891-902. PMID: 31174999.
      Citations:    
    68. Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick D, Rippon GA, Klatt J, Xue F, Chia V, Zhang F, Cheng S, Mikol DD. Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019 May 30; 333102419854082. PMID: 31146544.
      Citations:    
    69. Dodick DW, Silberstein SD, Lipton RB, DeGryse RE, Adams AM, Diener HC. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data. Cephalalgia. 2019 Jul; 39(8):945-956. PMID: 31112399.
      Citations:    
    70. Balaban CD, Black RD, Silberstein SD. Vestibular Neuroscience for the Headache Specialist. Headache. 2019 May 11. PMID: 31077365.
      Citations:    
    71. Yarnitsky D, Dodick DW, Grosberg BM, Burstein R, Ironi A, Harris D, Lin T, Silberstein SD. Remote Electrical Neuromodulation (REN) Relieves Acute Migraine: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial. Headache. 2019 May 09. PMID: 31074005.
      Citations:    
    72. Deen M, Martinelli D, Pijpers J, Diener HC, Silberstein S, Ferrari MD, Ashina M, Tassorelli C, Yuan H. Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults. Cephalalgia. 2019 May 01; 333102419847751. PMID: 31042062.
      Citations:    
    73. Lipton RB, Tepper SJ, Reuter U, Silberstein S, Stewart WF, Nilsen J, Leonardi DK, Desai P, Cheng S, Mikol DD, Lenz R. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. Neurology. 2019 May 07; 92(19):e2250-e2260. PMID: 30996060.
      Citations:    
    74. Silberstein SD, McAllister P, Ning X, Faulhaber N, Lang N, Yeung P, Schiemann J, Aycardi E, Cohen JM, Janka L, Yang R. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials. Headache. 2019 Apr 12. PMID: 30977520.
      Citations:    
    75. Parikh SK, Silberstein SD. Current Status of Antiepileptic Drugs as Preventive Migraine Therapy. Curr Treat Options Neurol. 2019 Mar 18; 21(4):16. PMID: 30880369.
      Citations:    
    76. Jain S, Silberstein SD. Invited Commentary on Preventive Anti-Migraine Therapy (PAMT). Curr Treat Options Neurol. 2019 Mar 14; 21(4):14. PMID: 30868470.
      Citations:    
    77. Tassorelli C, Greco R, Silberstein SD. The endocannabinoid system in migraine: from bench to pharmacy and back. Curr Opin Neurol. 2019 Mar 14. PMID: 30883435.
      Citations:    
    78. Pavlovic JM, Yu JS, Silberstein SD, Reed ML, Kawahara SH, Cowan RP, Dabbous F, Campbell KL, Shewale AR, Pulicharam R, Kowalski JW, Viswanathan HN, Lipton RB. Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients. Cephalalgia. 2019 Mar 09; 333102418825373. PMID: 30854881.
      Citations:    
    79. Diener HC, Tassorelli C, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ, Mandrekar J. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. Cephalalgia. 2019 Feb 26; 333102419828967. PMID: 30806518.
      Citations:    
    80. Yuan H, White CS, Silberstein SD. CGRP antagonists in the treatment of episodic migraine. Clin Pharmacol Ther. 2019 Jan 16. PMID: 30648737.
      Citations:    
    81. Lipton RB, Silberstein S. Migraine Headache: Diagnosis and Current and Emerging Preventive Treatments. Prim Care Companion CNS Disord. 2018 Dec 27; 20 suppl E1. PMID: 30698925.
      Citations:    
    82. Silberstein SD, Rapoport AM, Loupe PS, Aycardi E, McDonald M, Yang R, Bigal ME. The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment. Headache. 2018 Nov 18. PMID: 30450545.
      Citations:    
    83. Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018 Dec 11; 91(24):e2222-e2232. PMID: 30446595.
      Citations:    
    84. Levin M, Silberstein SD, Gilbert R, Lucas S, Munsie L, Garrelts A, Kennedy K, Everman N, Pearlman E. Basic Considerations for the Use of Monoclonal Antibodies in Migraine. Headache. 2018 11; 58(10):1689-1696. PMID: 30426478.
      Citations:    
    85. Silberstein SD, Lee L, Gandhi K, Fitzgerald T, Bell J, Cohen JM. Health care Resource Utilization and Migraine Disability Along the Migraine Continuum Among Patients Treated for Migraine. Headache. 2018 Nov; 58(10):1579-1592. PMID: 30375650.
      Citations:    
    86. Bigal ME, Rapoport AM, Silberstein SD, Walter S, Hargreaves RJ, Aycardi E. From LBR-101 to Fremanezumab for Migraine. CNS Drugs. 2018 Oct 11. PMID: 30311143.
      Citations:    
    87. Jain S, Yuan H, Spare N, Silberstein SD. Erenumab in the treatment of migraine. Pain Manag. 2018 Sep 21. PMID: 30235976.
      Citations:    
    88. Lauritsen CG, Silberstein SD. Rationale for electrical parameter determination in external trigeminal nerve stimulation (eTNS) for migraine: A narrative review. Cephalalgia. 2018 Aug 23; 333102418796781. PMID: 30139273.
      Citations:    
    89. Schwenk ES, Dayan AC, Rangavajjula A, Torjman MC, Hernandez MG, Lauritsen CG, Silberstein SD, Young W, Viscusi ER. Ketamine for Refractory Headache: A Retrospective Analysis. Reg Anesth Pain Med. 2018 Jun 19. PMID: 29923953.
      Citations:    
    90. Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. JAMA. 2018 05 15; 319(19):1999-2008. PMID: 29800211.
      Citations:    
    91. Frampton JE, Silberstein S. Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs. 2018 Apr; 78(6):715. PMID: 29679281.
      Citations:    
    92. Frampton JE, Silberstein S. OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine. Drugs. 2018 Apr; 78(5):589-600. PMID: 29532439.
      Citations:    
    93. Berk T, Silberstein SD. The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders. Headache. 2018 Mar 14. PMID: 29536530.
      Citations:    
    94. Silberstein SD, Yeung PP, Aycardi E. Preventive Therapies for Chronic Migraine. N Engl J Med. 2018 02 22; 378(8):774. PMID: 29466162.
      Citations:    
    95. Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018 Jan 01; 333102418762525. PMID: 29504483.
      Citations:    
    96. Tassorelli C, Diener HC, Dodick DW, Silberstein SD, Lipton RB, Ashina M, Becker WJ, Ferrari MD, Goadsby PJ, Pozo-Rosich P, Wang SJ. Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults. Cephalalgia. 2018 Jan 01; 333102418758283. PMID: 29504482.
      Citations:    
    97. Tobis JM, Charles A, Silberstein SD, Sorensen S, Maini B, Horwitz PA, Gurley JC. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial. J Am Coll Cardiol. 2017 Dec 05; 70(22):2766-2774. PMID: 29191325.
      Citations:    
    98. Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress. BioDrugs. 2017 Dec; 31(6):487-501. PMID: 29116598.
      Citations:    
    99. Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017 11 30; 377(22):2113-2122. PMID: 29171818.
      Citations:    
    100. Silberstein SD, Calhoun AH, Treppendahl C, Dodick DW, Rapoport AM, Mamidi A, Vargas P, Ebert TH, Tepper SJ. The emerging role of gammaCore® in the management of cluster headache: expert panel recommendations. Am J Manag Care. 2017 Nov; 23(17 Suppl):S326-S333. PMID: 29144718.
      Citations:    
    101. Silberstein SD. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine. Expert Opin Drug Saf. 2018 Jan; 17(1):89-97. PMID: 28994319.
      Citations:    
    102. Lipton RB, McGinley JS, Shulman KJ, Silberstein SD, Wirth RJ, Buse DC. AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial. Headache. 2018 Feb; 58(2):229-242. PMID: 29034453.
      Citations:    
    103. Yuan H, Silberstein SD. Histamine and Migraine. Headache. 2018 Jan; 58(1):184-193. PMID: 28862769.
      Citations:    
    104. Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F, Gage JR, Cheng S, Mikol DD, Lenz RA. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology. 2017 Sep 19; 89(12):1237-1243. PMID: 28835404.
      Citations:    
    105. Silberstein S. AVP-825: a novel intranasal delivery system for low-dose sumatriptan powder in the treatment of acute migraine. Expert Rev Clin Pharmacol. 2017 Jul 03; 1-12. PMID: 28605258.
      Citations:    
    106. Silberstein S, Winner PK, McAllister PJ, Tepper SJ, Halker R, Mahmoud RA, Siffert J. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered® Exhalation Delivery System (Sumatriptan Nasal Powder) vs Oral Sumatriptan. Headache. 2017 Jun; 57(6):862-876. PMID: 28497569.
      Citations:    
    107. Silberstein SD. Neuropeptides. Headache. 2017 May; 57 Suppl 2:35-36. PMID: 28485847.
      Citations:    
    108. Tepper S, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein S, Winner P, Leonardi D, Mikol D, Lenz R. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jun; 16(6):425-434. PMID: 28460892.
      Citations:    
    109. Blumenfeld AM, Silberstein SD, Dodick DW, Aurora SK, Brin MF, Binder WJ. Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal Outcomes. Headache. 2017 May; 57(5):766-777. PMID: 28387038.
      Citations:    
    110. Silberstein SD. Topiramate in Migraine Prevention: A 2016 Perspective. Headache. 2017 Jan; 57(1):165-178. PMID: 27902848.
      Citations:    
    111. Silberstein SD, Mechtler LL, Kudrow DB, Calhoun AH, McClure C, Saper JR, Liebler EJ, Rubenstein Engel E, Tepper SJ. Non-Invasive Vagus Nerve Stimulation for the ACute Treatment of Cluster Headache: Findings From the Randomized, Double-Blind, Sham-Controlled ACT1 Study. Headache. 2016 Sep; 56(8):1317-32. PMID: 27593728.
      Citations:    
    112. Chua AL, Silberstein S. Inhaled drug therapy development for the treatment of migraine. Expert Opin Pharmacother. 2016 Sep; 17(13):1733-43. PMID: 27416108.
      Citations:    
    113. Silberstein SD, Calhoun AH, Lipton RB, Grosberg BM, Cady RK, Dorlas S, Simmons KA, Mullin C, Liebler EJ, Goadsby PJ, Saper JR. Chronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study. Neurology. 2016 Aug 2; 87(5):529-38. PMID: 27412146.
      Citations:    
    114. Silberstein SD. The American Headache Society Cluster Guidelines. Headache. 2016 Jul; 56(7):1091-2. PMID: 27432622.
      Citations:    
    115. Giffin NJ, Lipton RB, Silberstein SD, Olesen J, Goadsby PJ. The migraine postdrome: An electronic diary study. Neurology. 2016 Jul 19; 87(3):309-13. PMID: 27335112.
      Citations:    
    116. Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S. How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine. Headache. 2016 Jul; 56(7):1194-200. PMID: 27322907.
      Citations:    
    117. Silberstein S. The Management of Adults With Acute Migraine in the Emergency Department. Headache. 2016 Jun; 56(6):907-8. PMID: 27300481.
      Citations:    
    118. Piovesan EJ, Oshinsky M, Silberstein S, Kowacs PA, Novak EM, Werneck LC. Botulinum neurotoxin type-A when utilized in animals with trigeminal sensitization induced a antinociceptive effect. Arq Neuropsiquiatr. 2016 Jun; 74(6):462-9. PMID: 27332071.
      Citations:    
    119. Silberstein SD. Considerations for management of migraine symptoms in the primary care setting. Postgrad Med. 2016 Jun; 128(5):523-37. PMID: 27078039.
      Citations:    
    120. Wrobel Goldberg S, Silberstein SD. Erratum to: Targeting CGRP: A New Era for Migraine Treatment. CNS Drugs. 2016 04; 30(4):355. PMID: 27067342.
      Citations:    
    121. Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M, Saper J, Cady R, Chon Y, Dietrich J, Lenz R. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Apr; 15(4):382-90. PMID: 26879279.
      Citations:    
    122. Silberstein SD. The Use of Botulinum Toxin in the Management of Headache Disorders. Semin Neurol. 2016 Feb; 36(1):92-8. PMID: 26866501.
      Citations:    
    123. Clark SW, Wu C, Boorman DW, Chalouhi N, Zanaty M, Oshinsky M, Young WB, Silberstein SD, Sharan AD. Long-Term Pain Reduction Does Not Imply Improved Functional Outcome in Patients Treated With Combined Supraorbital and Occipital Nerve Stimulation for Chronic Migraine. Neuromodulation. 2016 Jul; 19(5):507-14. PMID: 26861893.
      Citations:    
    124. Berk T, Silberstein S. Case Report: Secondary SUNCT After Radiation Therapy-A Novel Presentation. Headache. 2016 Feb; 56(2):397-401. PMID: 26643474.
      Citations:    
    125. Yuan H, Silberstein SD. Vagus Nerve Stimulation and Headache. Headache. 2017 Apr; 57 Suppl 1:29-33. PMID: 26473407.
      Citations:    
    126. Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R, Loupe PS, Burstein R, Newman LC, Lipton RB. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov; 14(11):1081-90. PMID: 26432182.
      Citations:    
    127. Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC, Burstein R, Loupe PS, Ma Y, Yang R, Silberstein SD. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov; 14(11):1091-100. PMID: 26432181.
      Citations:    
    128. Yuan H, Silberstein SD. Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part II. Headache. 2016 Feb; 56(2):259-66. PMID: 26381725.
      Citations:    
    129. Yuan H, Silberstein SD. Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part III. Headache. 2016 Mar; 56(3):479-90. PMID: 26364805.
      Citations:    
    130. Yuan H, Silberstein SD. Vagus Nerve and Vagus Nerve Stimulation, a Comprehensive Review: Part I. Headache. 2016 Jan; 56(1):71-8. PMID: 26364692.
      Citations:    
    131. Silberstein S, Lenz R, Xu C. Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know. Headache. 2015 Sep; 55(8):1171-82. PMID: 26316307.
      Citations:    
    132. Silberstein SD. Preventive Migraine Treatment. Continuum (Minneap Minn). 2015 Aug; 21(4 Headache):973-89. PMID: 26252585.
      Citations:    
    133. Bigal ME, Lipton RB, Newman LC, Pierce MW, Silberstein SD. Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial. Headache. 2015 Sep; 55(8):1124-32. PMID: 26178815.
      Citations:    
    134. Wrobel Goldberg S, Silberstein SD. Targeting CGRP: A New Era for Migraine Treatment. CNS Drugs. 2015 Jun; 29(6):443-52. PMID: 26138383.
      Citations:    
    135. Tepper SJ, Cady RK, Silberstein S, Messina J, Mahmoud RA, Djupesland PG, Shin P, Siffert J. AVP-825 Breath-Powered Intranasal Delivery System Containing 22?mg Sumatriptan Powder vs 100?mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks. Headache. 2015 May; 55(5):621-35. PMID: 25941016.
      Citations:    
    136. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015 Mar; 55 Suppl 2:103-22. PMID: 25662743.
      Citations:    
    137. St Cyr A, Chen A, Bradley KC, Yuan H, Silberstein SD, Young WB. Efficacy and Tolerability of STOPAIN for a Migraine Attack. Front Neurol. 2015; 6:11. PMID: 25699012.
      Citations:    
    138. Silberstein SD, Marmura MJ. Acute migraine treatment. Headache. 2015 Jan; 55(1):1-2. PMID: 25600717.
      Citations:    
    139. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan; 55(1):3-20. PMID: 25600718.
      Citations:    
    140. Silberstein SD, Silvestrini M. Does migraine produce facial palsy? For whom the Bell tolls. Neurology. 2015 Jan 13; 84(2):108-9. PMID: 25520314.
      Citations:    
    141. Vongvaivanich K, Lertakyamanee P, Silberstein SD, Dodick DW. Late-life migraine accompaniments: A narrative review. Cephalalgia. 2015 Sep; 35(10):894-911. PMID: 25505036.
      Citations:    
    142. Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry. 2015 Sep; 86(9):996-1001. PMID: 25500317.
      Citations:    
    143. Dodick DW, Turkel CC, DeGryse RE, Diener HC, Lipton RB, Aurora SK, Nolan ME, Silberstein SD. Assessing clinically meaningful treatment effects in controlled trials: chronic migraine as an example. J Pain. 2015 Feb; 16(2):164-75. PMID: 25464159.
      Citations:    
    144. Wrobel Goldberg S, Silberstein S, Grosberg BM. Considerations in the treatment of tension-type headache in the elderly. Drugs Aging. 2014 Nov; 31(11):797-804. PMID: 25315108.
      Citations:    
    145. Silberstein SD. TRPV1, CGRP and SP in scalp arteries of patients suffering from chronic migraine. Some like it hot! Chronic migraine increases TRPV1 receptors in the scalp. J Neurol Neurosurg Psychiatry. 2015 Apr; 86(4):361. PMID: 25288609.
      Citations:    
    146. Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014 Nov; 13(11):1100-7. PMID: 25297013.
      Citations:    
    147. Dougherty C, Silberstein SD. Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment, and Management. Pain Pract. 2015 Sep; 15(7):688-92. PMID: 25271173.
      Citations:    
    148. Silberstein S, Patel S. Menstrual migraine: an updated review on hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother. 2014 Oct; 15(14):2063-70. PMID: 25100506.
      Citations:    
    149. Dodick DW, Silberstein SD, Reed KL, Deer TR, Slavin KV, Huh B, Sharan AD, Narouze S, Mogilner AY, Trentman TL, Ordia J, Vaisman J, Goldstein J, Mekhail N. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Long-term results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2015 Apr; 35(4):344-58. PMID: 25078718.
      Citations:    
    150. Silberstein SD, Stirpe JC. COX inhibitors for the treatment of migraine. Expert Opin Pharmacother. 2014 Sep; 15(13):1863-74. PMID: 25010639.
      Citations:    
    151. Silberstein SD, Lipton RB, Dodick DW. Operational diagnostic criteria for chronic migraine: expert opinion. Headache. 2014 Jul; 54(7):1258-66. PMID: 24990187.
      Citations:    
    152. Silberstein SD. Is the migraine brain super-active? Pain. 2014 Jun; 155(6):1049-50. PMID: 24631595.
      Citations:    
    153. Marmura MJ, Silberstein SD. Headaches caused by nasal and paranasal sinus disease. Neurol Clin. 2014 May; 32(2):507-23. PMID: 24703542.
      Citations:    
    154. Loder E, Weizenbaum E, Frishberg B, Silberstein S. Temporarily Withdrawn: Choosing Wisely in Headache Medicine: The American Headache Society's List of Five Things Physicians and Patients Should Question. Headache. 2013 Nov 08. PMID: 24205799.
      Citations:    
    155. Loder E, Weizenbaum E, Frishberg B, Silberstein S. Choosing Wisely in Headache Medicine: The American Headache Society's List of Five Things Physicians and Patients Should Question. Headache. 2013 Nov; 53(10):1651-9. PMID: 24266337.
      Citations:    
    156. Bhambri R, Martin VT, Abdulsattar Y, Silberstein S, Almas M, Chatterjee A, Ramos E. Comparing the efficacy of eletriptan for migraine in women during menstrual and non-menstrual time periods: a pooled analysis of randomized controlled trials. Headache. 2014 Feb; 54(2):343-54. PMID: 24256184.
      Citations:    
    157. Silberstein S, McDonald SA, Goldstein J, Aurora S, Lener SE, White J, Runken MC, Saiers J, Derosier F, Lipton RB. Sumatriptan/naproxen sodium for the acute treatment of probable migraine without aura: A randomized study. Cephalalgia. 2014 Apr; 34(4):268-79. PMID: 24108307.
      Citations:    
    158. Gibofsky A, Silberstein S, Argoff C, Daniels S, Jensen S, Young CL. Lower-dose diclofenac submicron particle capsules provide early and sustained acute patient pain relief in a phase 3 study. Postgrad Med. 2013 Sep; 125(5):130-8. PMID: 24113671.
      Citations:    
    159. Silberstein SD, Edvinsson L. Is CGRP a marker for chronic migraine? Neurology. 2013 Oct 1; 81(14):1184-5. PMID: 23975870.
      Citations:    
    160. Silberstein SD, Dodick DW. Migraine Genetics: Part II. Headache. 2013 Sep; 53(8):1218-29. PMID: 23919895.
      Citations:    
    161. Silberstein S, Dodick D. Migraine genetics - a review: part I. Headache. 2013 Sep; 53(8):1207-17. PMID: 23848970.
      Citations:    
    162. Silberstein SD, Marcus DA. Sumatriptan : treatment across the full spectrum of migraine. Expert Opin Pharmacother. 2013 Aug; 14(12):1659-67. PMID: 23786565.
      Citations:    
    163. Silberstein SD, Blumenfeld AM, Cady RK, Turner IM, Lipton RB, Diener HC, Aurora SK, Sirimanne M, Degryse RE, Turkel CC, Dodick DW. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline. J Neurol Sci. 2013 Aug 15; 331(1-2):48-56. PMID: 23790235.
      Citations:    
    164. Silberstein S. Gastrointestinal manifestations of migraine: meeting the treatment challenges. Headache. 2013 Jun; 53 Suppl 1:1-3. PMID: 23721283.
      Citations:    
    165. Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013 May; 27(5):385-94. PMID: 23620146.
      Citations:    
    166. Hutchinson S, Marmura MJ, Calhoun A, Lucas S, Silberstein S, Peterlin BL. Use of common migraine treatments in breast-feeding women: a summary of recommendations. Headache. 2013 Apr; 53(4):614-27. PMID: 23465038.
      Citations:    
    167. Silberstein SD, Vodovskaia N. Trigeminal autonomic cephalalgias other than cluster headache. Med Clin North Am. 2013 Mar; 97(2):321-8. PMID: 23419629.
      Citations:    
    168. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C. Author response. Neurology. 2013 Feb 26; 80(9):868-9. PMID: 23565553.
      Citations:    
    169. Blumenfeld A, Ashkenazi A, Napchan U, Bender SD, Klein BC, Berliner R, Ailani J, Schim J, Friedman DI, Charleston L, Young WB, Robertson CE, Dodick DW, Silberstein SD, Robbins MS. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches - a narrative review. Headache. 2013 Mar; 53(3):437-46. PMID: 23406160.
      Citations:    
    170. Goadsby PJ, Silberstein SD. Migraine triggers: Harnessing the messages of clinical practice. Neurology. 2013 Jan 29; 80(5):424-5. PMID: 23345640.
      Citations:    
    171. Silberstein S, Goode-Sellers S, Twomey C, Saiers J, Ascher J. Randomized, double-blind, placebo-controlled, phase II trial of gabapentin enacarbil for migraine prophylaxis. Cephalalgia. 2013 Jan; 33(2):101-11. PMID: 23165696.
      Citations:    
    172. Buse DC, Silberstein SD, Manack AN, Papapetropoulos S, Lipton RB. Psychiatric comorbidities of episodic and chronic migraine. J Neurol. 2013 Aug; 260(8):1960-9. PMID: 23132299.
      Citations:    
    173. Hansen JM, Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Goadsby PJ, Charles A. Migraine headache is present in the aura phase: a prospective study. Neurology. 2012 Nov 13; 79(20):2044-9. PMID: 23115208.
      Citations:    
    174. Silberstein SD, Dodick DW, Saper J, Huh B, Slavin KV, Sharan A, Reed K, Narouze S, Mogilner A, Goldstein J, Trentman T, Vaisma J, Ordia J, Weber P, Deer T, Levy R, Diaz RL, Washburn SN, Mekhail N. Safety and efficacy of peripheral nerve stimulation of the occipital nerves for the management of chronic migraine: Results from a randomized, multicenter, double-blinded, controlled study. Cephalalgia. 2012 Dec; 32(16):1165-79. PMID: 23034698.
      Citations:    
    175. Oshinsky ML, Sanghvi MM, Maxwell CR, Gonzalez D, Spangenberg RJ, Cooper M, Silberstein SD. Spontaneous trigeminal allodynia in rats: a model of primary headache. Headache. 2012 Oct; 52(9):1336-49. PMID: 22963523.
      Citations:    
    176. Silberstein S. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother. 2012 Sep; 13(13):1961-8. PMID: 22860628.
      Citations:    
    177. Pracilio VP, Silberstein S, Couto J, Bumbaugh J, Hopkins M, Ng-Mak D, Sennett C, Goldfarb NI. Measuring migraine-related quality of care across 10 health plans. Am J Manag Care. 2012 Aug; 18(8):e291-9. PMID: 22928798.
      Citations:    
    178. Smith TR, Goldstein J, Singer R, Pugach N, Silberstein S, Pierce MW. Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Headache. 2012 Apr; 52(4):612-24. PMID: 22352764.
      Citations:    
    179. Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine--classification, characteristics and treatment. Nat Rev Neurol. 2011; 8(3):162-71. PMID: 22331030.
      Citations:    
    180. Tepper SJ, Kori SH, Borland SW, Wang MH, Hu B, Mathew NT, Silberstein SD. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache. 2012 Jan; 52(1):37-47. PMID: 22106843.
      Citations:    
    181. Derosier F, Sheftell F, Silberstein S, Cady R, Ruoff G, Krishen A, Peykamian M. Sumatriptan-naproxen and butalbital: a double-blind, placebo-controlled crossover study. Headache. 2012 Apr; 52(4):530-43. PMID: 22103635.
      Citations:    
    182. Tepper SJ, Kori SH, Goadsby PJ, Winner PK, Wang MH, Silberstein SD, Cutrer FM. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc. 2011 Oct; 86(10):948-55. PMID: 21964172.
      Citations:    
    183. Schievink WI, Dodick DW, Mokri B, Silberstein S, Bousser MG, Goadsby PJ. Diagnostic criteria for headache due to spontaneous intracranial hypotension: a perspective. Headache. 2011 Oct; 51(9):1442-4. PMID: 21658029.
      Citations:    
    184. Silberstein SD, Robbins MS. Targeting sleep disruption using sodium oxybate in chronic cluster headache prophylaxis. Neurology. 2011 Jul 5; 77(1):16-7. PMID: 21613603.
      Citations:    
    185. Dodick DW, Turkel CC, Degryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: a response. Headache. 2011 Jun; 51(6):1005-8. PMID: 21592099.
      Citations:    
    186. Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, Dodick DW. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011 Apr; 51(4):507-17. PMID: 21457235.
      Citations:    
    187. Marmura MJ, Silberstein SD. Current understanding and treatment of headache disorders: five new things. Neurology. 2011 Feb 15; 76(7 Suppl 2):S31-6. PMID: 21321349.
      Citations:    
    188. Latsko M, Silberstein S, Rosen N. Frovatriptan as preemptive treatment for fasting-induced migraine. Headache. 2011 Mar; 51(3):369-74. PMID: 21269298.
      Citations:    
    189. Maxwell CR, Spangenberg RJ, Hoek JB, Silberstein SD, Oshinsky ML. Acetate causes alcohol hangover headache in rats. PLoS One. 2010; 5(12):e15963. PMID: 21209842.
      Citations:    
    190. Karp BI, Sinaii N, Nieman LK, Silberstein SD, Stratton P. Migraine in women with chronic pelvic pain with and without endometriosis. Fertil Steril. 2011 Mar 1; 95(3):895-9. PMID: 21145540.
      Citations:    
    191. Silberstein S. A new frontier for headache. Front Neurol. 2010; 1:135. PMID: 21206520.
      Citations:    
    192. Silberstein SD. Predicting the probability of relapse after discontinuation of migraine preventive treatment with topiramate. Cephalalgia. 2010 Nov; 30(11):1283. PMID: 20921027.
      Citations:    
    193. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache. 2010 Oct; 50(9):1406-18. PMID: 20958294.
      Citations:    
    194. Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache. 2010 Oct; 50(9):1499-506. PMID: 20958296.
      Citations:    
    195. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. Occipital nerve stimulation for the treatment of intractable chronic migraine headache: ONSTIM feasibility study. Cephalalgia. 2011 Feb; 31(3):271-85. PMID: 20861241.
      Citations:    
    196. Ho AP, Dahlöf CG, Silberstein SD, Saper JR, Ashina M, Kost JT, Froman S, Leibensperger H, Lines CR, Ho TW. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010 Dec; 30(12):1443-57. PMID: 20974601.
      Citations:    
    197. Lipton RB, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, Biondi DM, Ascher S, Olson WH, Hulihan J. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia. 2011 Jan; 31(1):18-30. PMID: 20974598.
      Citations:    
    198. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener HC, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010 Jun; 50(6):921-36. PMID: 20487038.
      Citations:    
    199. Silberstein SD. Association between restless legs syndrome and migraine. J Neurol Neurosurg Psychiatry. 2010 May; 81(5):473-5. PMID: 20460586.
      Citations:    
    200. Silberstein SD. Meeting acute migraine treatment needs through novel treatment formulations. Neurotherapeutics. 2010 Apr; 7(2):153-8. PMID: 20430313.
      Citations:    
    201. Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, Fischell RE, Ruppel PL, Goadsby PJ. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010 Apr; 9(4):373-80. PMID: 20206581.
      Citations:    
    202. Schwedt TJ, Silberstein SD. 14th International Headache Congress: clinical highlights. Headache. 2010 Mar; 50(3):509-19. PMID: 20456145.
      Citations:    
    203. Silberstein SD. Migraine preventive treatment. Handb Clin Neurol. 2010; 97:337-54. PMID: 20816433.
      Citations:    
    204. Cady RK, Goldstein J, Silberstein S, Juhász M, Ramsey K, Rodgers A, Hustad CM, Ho T. Expanding access to triptans: assessment of clinical outcome. Headache. 2009 Nov-Dec; 49(10):1402-13. PMID: 19817885.
      Citations:    
    205. MacGregor EA, Brandes JL, Silberstein S, Jeka S, Czapinski P, Shaw B, Pawsey S. Safety and tolerability of short-term preventive frovatriptan: a combined analysis. Headache. 2009 Oct; 49(9):1298-314. PMID: 19788471.
      Citations:    
    206. Silberstein SD, Berner T, Tobin J, Xiang Q, Campbell JC. Scheduled short-term prevention with frovatriptan for migraine occurring exclusively in association with menstruation. Headache. 2009 Oct; 49(9):1283-97. PMID: 19751371.
      Citations:    
    207. Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, Bigal M, Ascher S, Morein J, Wright P, Greenberg S, Hulihan J. Topiramate treatment of chronic migraine: a randomized, placebo-controlled trial of quality of life and other efficacy measures. Headache. 2009 Sep; 49(8):1153-62. PMID: 19719543.
      Citations:    
    208. Silberstein SD, Marmura MJ, Shaw J, Yu S. Headache prophylaxis with BoNTA: patient characteristics. Headache. 2010 Jan; 50(1):63-70. PMID: 19549156.
      Citations:    
    209. Silberstein SD. Preventive migraine treatment. Neurol Clin. 2009 May; 27(2):429-43. PMID: 19289224.
      Citations:    
    210. Manack A, Turkel C, Silberstein S. The evolution of chronic migraine: classification and nomenclature. Headache. 2009 Sep; 49(8):1206-13. PMID: 19438732.
      Citations:    
    211. Bigal ME, Ferrari M, Silberstein SD, Lipton RB, Goadsby PJ. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache. 2009 Feb; 49 Suppl 1:S21-33. PMID: 19161562.
      Citations:    
    212. Rosen N, Marmura M, Abbas M, Silberstein S. Intravenous lidocaine in the treatment of refractory headache: a retrospective case series. Headache. 2009 Feb; 49(2):286-91. PMID: 19222600.
      Citations:    
    213. Burstein R, Dodick D, Silberstein S. Migraine prophylaxis with botulinum toxin A is associated with perception of headache. Toxicon. 2009 Oct; 54(5):624-7. PMID: 19344670.
      Citations:    
    214. Ashkenazi A, Silberstein S. Is botulinum toxin useful in treating headache? Yes. Curr Treat Options Neurol. 2009 Jan; 11(1):18-23. PMID: 19094832.
      Citations:    
    215. Silberstein SD, Hutchinson SL. Diagnosis and treatment of the menstrual migraine patient. Headache. 2008 Nov-Dec; 48 Suppl 3:S115-23. PMID: 19076657.
      Citations:    
    216. Hutchinson SL, Silberstein SD. Menstrual migraine: case studies of women with estrogen-related headaches. Headache. 2008 Nov-Dec; 48 Suppl 3:S131-41. PMID: 19076659.
      Citations:    
    217. Silberstein SD. Recent developments in migraine. Lancet. 2008 Oct 18; 372(9647):1369-71. PMID: 18940454.
      Citations:    
    218. Leas BF, Gagne JJ, Goldfarb NI, Rupnow MF, Silberstein S. Assessing quality of care for migraineurs: a model health plan measurement set. Popul Health Manag. 2008 Aug; 11(4):203-8. PMID: 18942925.
      Citations:    
    219. Silberstein SD. Treatment recommendations for migraine. Nat Clin Pract Neurol. 2008 Sep; 4(9):482-9. PMID: 18665146.
      Citations:    
    220. Silberstein S, Diener HC, Lipton R, Goadsby P, Dodick D, Bussone G, Freitag F, Schwalen S, Ascher S, Morein J, Greenberg S, Biondi D, Hulihan J. Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache. 2008 Jul; 48(7):1087-95. PMID: 18687081.
      Citations:    
    221. Goadsby PJ, Goldberg J, Silberstein SD. Migraine in pregnancy. BMJ. 2008 Jun 28; 336(7659):1502-4. PMID: 18583683.
      Citations:    
    222. Schere D, Silberstein SD. Intravenous lidocaine infusion for the treatment of post-acoustic neuroma resection headache: a case report. Headache. 2009 Feb; 49(2):302-3. PMID: 18549411.
      Citations:    
    223. Mendelson J, Muppidi S, Silberstein S. Multiple intracerebral hemorrhages after cervical epidural injections. Neurology. 2008 Jun 10; 70(24 Pt 2):2415-6. PMID: 18541877.
      Citations:    
    224. Matchar DB, Harpole L, Samsa GP, Jurgelski A, Lipton RB, Silberstein SD, Young W, Kori S, Blumenfeld A. The headache management trial: a randomized study of coordinated care. Headache. 2008 Oct; 48(9):1294-310. PMID: 18547268.
      Citations:    
    225. Nahas SJ, Silberstein SD. Triptans: actions and reactions. Headache. 2008 Apr; 48(4):611-3. PMID: 18377383.
      Citations:    
    226. Piovesan EJ, Sobreira CF, Scola RH, Lorenzoni PJ, Lange MC, Werneck LC, Smith D, Silberstein S. Episodic migraine associated with postural orthostatic tachycardia syndrome and vasovagal syncope: migraine triggers neuromediated syncope. Arq Neuropsiquiatr. 2008 Mar; 66(1):77-9. PMID: 18392420.
      Citations:    
    227. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF. Cutaneous allodynia in the migraine population. Ann Neurol. 2008 Feb; 63(2):148-58. PMID: 18059010.
      Citations:    
    228. Ashkenazi A, Silberstein S. Botulinum toxin type A for the treatment of headache: why we say yes. Arch Neurol. 2008 Jan; 65(1):146-9. PMID: 18195155.
      Citations:    
    229. Tuchman MM, Hee A, Emeribe U, Silberstein S. Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study. CNS Drugs. 2008; 22(10):877-86. PMID: 18788838.
      Citations:    
    230. Dodick DW, Silberstein S, Saper J, Freitag FG, Cady RK, Rapoport AM, Mathew NT, Hulihan J, Crivera C, Rupnow MF, Mao L, Finlayson G, Greenberg SJ. The impact of topiramate on health-related quality of life indicators in chronic migraine. Headache. 2007 Nov-Dec; 47(10):1398-408. PMID: 18052949.
      Citations:    
    231. Silberstein SD, Goldberg J. Menstrually related migraine: breaking the cycle in your clinical practice. J Reprod Med. 2007 Oct; 52(10):888-95. PMID: 17977161.
      Citations:    
    232. Gupta MX, Silberstein SD, Young WB, Hopkins M, Lopez BL, Samsa GP. Less is not more: underutilization of headache medications in a university hospital emergency department. Headache. 2007 Sep; 47(8):1125-33. PMID: 17883517.
      Citations:    
    233. Ashkenazi A, Silberstein S. Menstrual migraine: a review of hormonal causes, prophylaxis and treatment. Expert Opin Pharmacother. 2007 Aug; 8(11):1605-13. PMID: 17685879.
      Citations:    
    234. Silberstein SD, Young WB, Hopkins MM, Gebeline-Myers C, Bradley KC. Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial. Headache. 2007 Jun; 47(6):878-85. PMID: 17578539.
      Citations:    
    235. Gagne JJ, Leas B, Lofland JH, Goldfarb N, Freitag F, Silberstein S. Quality of care measures for migraine: a comprehensive review. Dis Manag. 2007 Jun; 10(3):138-46. PMID: 17590144.
      Citations:    
    236. Silberstein SD, Cady RK, Sheftell FD, Almas M, Parsons B, Albert KS. Efficacy of eletriptan in migraine-related functional impairment: functional and work productivity outcomes. Headache. 2007 May; 47(5):673-82. PMID: 17501848.
      Citations:    
    237. Silberstein SD, Feliu AL, Rupnow MF, Blount AC, Boccuzzi SJ. Topiramate in migraine prophylaxis: long-term impact on resource utilization and cost. Headache. 2007 Apr; 47(4):500-10. PMID: 17445099.
      Citations:    
    238. Peres MF, Silberstein S, Moreira F, Corchs F, Vieira DS, Abraham N, Gebeline-Myers C. Patients' preference for migraine preventive therapy. Headache. 2007 Apr; 47(4):540-5. PMID: 17445103.
      Citations:    
    239. Silberstein SD, Dodick D, Freitag F, Pearlman SH, Hahn SR, Scher AI, Lipton RB. Pharmacological approaches to managing migraine and associated comorbidities--clinical considerations for monotherapy versus polytherapy. Headache. 2007 Apr; 47(4):585-99. PMID: 17445108.
      Citations:    
    240. Silberstein SD. Diagnostic testing in episodic migraine: should it include magnetic resonance venography? Nat Clin Pract Neurol. 2007 May; 3(5):254-5. PMID: 17356532.
      Citations:    
    241. Lofland JH, Gagne JJ, Pizzi LT, Rupnow M, Silberstein SD. Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials. J Occup Environ Med. 2007 Mar; 49(3):252-7. PMID: 17351510.
      Citations:    
    242. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache. 2007 Mar; 47(3):355-63. PMID: 17371352.
      Citations:    
    243. Goldberg J, Wolf A, Silberstein S, Gebeline-Myers C, Hopkins M, Einhorn K, Tolosa JE. Evaluation of an electronic diary as a diagnostic tool to study headache and premenstrual symptoms in migraineurs. Headache. 2007 Mar; 47(3):384-96. PMID: 17371355.
      Citations:    
    244. Peres MF, Mercante JP, Guendler VZ, Corchs F, Bernik MA, Zukerman E, Silberstein SD. Cephalalgiaphobia: a possible specific phobia of illness. J Headache Pain. 2007 Feb; 8(1):56-9. PMID: 17361383.
      Citations:    
    245. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, Brandes JL, Bigal M, Saper J, Ascher S, Jordan DM, Greenberg SJ, Hulihan J. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007 Feb; 47(2):170-80. PMID: 17300356.
      Citations:    
    246. Reinecke RD, Silberstein SD. Migrainous visual auras: a life history. Headache. 2007 Jan; 47(1):123-7. PMID: 17355507.
      Citations:    
    247. Ashkenazi A, Abbas MA, Sharma DK, Silberstein SD. Hemicrania continua-like headache associated with internal carotid artery dissection may respond to indomethacin. Headache. 2007 Jan; 47(1):127-30. PMID: 17355508.
      Citations:    
    248. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006 Nov; 46 Suppl 4:S171-81. PMID: 17078849.
      Citations:    
    249. Dodick D, Silberstein S. Central sensitization theory of migraine: clinical implications. Headache. 2006 Nov; 46 Suppl 4:S182-91. PMID: 17078850.
      Citations:    
    250. Saper JR, Silberstein S, Dodick D, Rapoport A. DHE in the pharmacotherapy of migraine: potential for a larger role. Headache. 2006 Nov; 46 Suppl 4:S212-20. PMID: 17078853.
      Citations:    
    251. Silberstein SD. How effective is intensive migraine education provided by migraineurs? Nat Clin Pract Neurol. 2006 Oct; 2(10):526-7. PMID: 16990821.
      Citations:    
    252. Sun C, Lay C, Broner S, Silberstein S, Tepper S, Newman L. Reversible anorgasmia with topiramate therapy for headache: a report of 7 patients. Headache. 2006 Oct; 46(9):1450-3. PMID: 17040342.
      Citations:    
    253. Silberstein SD. Preventive treatment of migraine. Trends Pharmacol Sci. 2006 Aug; 27(8):410-5. PMID: 16820222.
      Citations:    
    254. Silberstein SD, Hulihan J, Karim MR, Wu SC, Jordan D, Karvois D, Kamin M. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study. Clin Ther. 2006 Jul; 28(7):1002-11. PMID: 16990078.
      Citations:    
    255. Silberstein SD, Loder E, Forde G, Papadopoulos G, Fairclough D, Greenberg S. The impact of migraine on daily activities: effect of topiramate compared with placebo. Curr Med Res Opin. 2006 Jun; 22(6):1021-9. PMID: 16846536.
      Citations:    
    256. Malik SN, Hopkins M, Young WB, Silberstein SD. Acute migraine treatment: patterns of use and satisfaction in a clinical population. Headache. 2006 May; 46(5):773-80. PMID: 16643580.
      Citations:    
    257. Silberstein SD, Ruoff G. Combination therapy in acute migraine treatment: the rationale behind the current treatment options. Postgrad Med. 2006 Apr; Spec No:20-6. PMID: 17960687.
      Citations:    
    258. Goldstein J, Silberstein SD, Saper JR, Ryan RE, Lipton RB. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache. 2006 Mar; 46(3):444-53. PMID: 16618262.
      Citations:    
    259. Ashkenazi A, Silberstein SD. Hormone-related headache: pathophysiology and treatment. CNS Drugs. 2006; 20(2):125-41. PMID: 16478288.
      Citations:    
    260. Tuchman M, Hee A, Emeribe U, Silberstein S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs. 2006; 20(12):1019-26. PMID: 17140280.
      Citations:    
    261. Jakubowski M, Silberstein S, Ashkenazi A, Burstein R. Can allodynic migraine patients be identified interictally using a questionnaire? Neurology. 2005 Nov 8; 65(9):1419-22. PMID: 16275830.
      Citations:    
    262. Silberstein SD, Freitag FG, Rozen TD, Kudrow DB, Hewitt DJ, Jordan DM, Fisher AC, Rosenthal NR. Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial. Headache. 2005 Nov-Dec; 45(10):1317-27. PMID: 16324164.
      Citations:    
    263. Kantor D, Silberstein SD. Cervical epidural blood patch for low CSF pressure headaches. Neurology. 2005 Oct 11; 65(7):1138. PMID: 16217080.
      Citations:    
    264. Silberstein SD, Dodick D, Kesslick J. Removing barriers to appropriate migraine treatment: formulary limitations and triptan package size. Headache. 2005 Oct; 45(9):1250-4. PMID: 16178957.
      Citations:    
    265. Silberstein SD. Headaches in pregnancy. J Headache Pain. 2005 Sep; 6(4):172-4. PMID: 16362655.
      Citations:    
    266. Martelletti P, Haimanot RT, Láinez MJ, Rapoport AM, Ravishankar K, Sakai F, Silberstein SD, Vincent M, Steiner TJ. The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE). J Headache Pain. 2005 Sep; 6(4):261-3. PMID: 16362681.
      Citations:    
    267. Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM, Battikha JP, Hoffman H, Baggish J. Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache. 2005 Sep; 45(8):973-82. PMID: 16109110.
      Citations:    
    268. Harpole LH, Samsa GP, Matchar DB, Silberstein SD, Blumenfeld A, Jurgelski AE. Burden of illness and satisfaction with care among patients with headache seen in a primary care setting. Headache. 2005 Sep; 45(8):1048-55. PMID: 16109119.
      Citations:    
    269. Silberstein SD, Stark SR, Lucas SM, Christie SN, Degryse RE, Turkel CC. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005 Sep; 80(9):1126-37. PMID: 16178492.
      Citations:    
    270. Silberstein SD. Cardiovascular risk factors associated with migraine. Lancet Neurol. 2005 Jul; 4(7):391-2. PMID: 15963440.
      Citations:    
    271. Silberstein SD. Preventive treatment of headaches. Curr Opin Neurol. 2005 Jun; 18(3):289-92. PMID: 15891414.
      Citations:    
    272. Gupta M, Silberstein SD. Therapeutic options in the management of headache attributed to rhinosinusitis. Expert Opin Pharmacother. 2005 May; 6(5):715-22. PMID: 15934898.
      Citations:    
    273. Rosenberg JH, Silberstein SD. The headache of SAH responds to sumatriptan. Headache. 2005 May; 45(5):597-8. PMID: 15953279.
      Citations:    
    274. Silberstein SD. Chronic daily headache. J Am Osteopath Assoc. 2005 Apr; 105(4 Suppl 2):23S-29S. PMID: 15928350.
      Citations:    
    275. Silberstein SD. Topiramate in migraine prevention. Headache. 2005 Apr; 45 Suppl 1:S57-65. PMID: 15833091.
      Citations:    
    276. Dodick DW, Mauskop A, Elkind AH, DeGryse R, Brin MF, Silberstein SD. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache. 2005 Apr; 45(4):315-24. PMID: 15836567.
      Citations:    
    277. Siow HC, Young WB, Silberstein SD. Neuroleptics in headache. Headache. 2005 Apr; 45(4):358-71. PMID: 15836574.
      Citations:    
    278. Silberstein SD, Ben-Menachem E, Shank RP, Wiegand F. Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther. 2005 Feb; 27(2):154-65. PMID: 15811478.
      Citations:    
    279. O'Connor W, Silberstein SD. MRI of a brain under pressure. Headache. 2005 Jan; 45(1):68-9. PMID: 15663615.
      Citations:    
    280. Silberstein SD. Headaches in pregnancy. Neurol Clin. 2004 Nov; 22(4):727-56. PMID: 15474764.
      Citations:    
    281. Silberstein SD. Migraine. Discov Med. 2004 Oct; 4(23):270-6. PMID: 20704958.
      Citations:    
    282. Ashkenazi A, Silberstein SD. Headache management for the pain specialist. Reg Anesth Pain Med. 2004 Sep-Oct; 29(5):462-75. PMID: 15372392.
      Citations:    
    283. Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology. 2004 Jul 27; 63(2):261-9. PMID: 15277618.
      Citations:    
    284. Rozen TD, Shanske S, Otaegui D, Lu J, Young WB, Bradley K, DiMauro S, Silberstein SD. Study of mitochondrial DNA mutations in patients with migraine with prolonged aura. Headache. 2004 Jul-Aug; 44(7):674-7. PMID: 15209689.
      Citations:    
    285. Young WB, Siow HC, Silberstein SD. Anticonvulsants in migraine. Curr Pain Headache Rep. 2004 Jun; 8(3):244-50. PMID: 15115645.
      Citations:    
    286. Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004 May; 44(5):414-25. PMID: 15147249.
      Citations:    
    287. Dodick DW, Martin VT, Smith T, Silberstein S. Cardiovascular tolerability and safety of triptans: a review of clinical data. Headache. 2004 May; 44 Suppl 1:S20-30. PMID: 15149490.
      Citations:    
    288. Silberstein SD, Neto W, Schmitt J, Jacobs D. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol. 2004 Apr; 61(4):490-5. PMID: 15096395.
      Citations:    
    289. Freitag FG, Lake A, Lipton R, Cady R, Diamond S, Silberstein S. Inpatient treatment of headache: an evidence-based assessment. Headache. 2004 Apr; 44(4):342-60. PMID: 15109359.
      Citations:    
    290. Blumenfeld AM, Dodick DW, Silberstein SD. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Dermatol Clin. 2004 Apr; 22(2):167-75. PMID: 15222577.
      Citations:    
    291. Silberstein S. Botulinum neurotoxins: origins and basic mechanisms of action. Pain Pract. 2004 Mar; 4 Suppl 1:S19-26. PMID: 17129272.
      Citations:    
    292. Loder E, Silberstein SD, Abu-Shakra S, Mueller L, Smith T. Efficacy and tolerability of oral zolmitriptan in menstrually associated migraine: a randomized, prospective, parallel-group, double-blind, placebo-controlled study. Headache. 2004 Feb; 44(2):120-30. PMID: 14756849.
      Citations:    
    293. Silberstein SD. Headaches due to nasal and paranasal sinus disease. Neurol Clin. 2004 Feb; 22(1):1-19, v. PMID: 15062525.
      Citations:    
    294. Silberstein SD. Migraine. Lancet. 2004 Jan 31; 363(9406):381-91. PMID: 15070571.
      Citations:    
    295. Dodick D, Blumenfeld A, Silberstein SD. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders. Clin Dermatol. 2004 Jan-Feb; 22(1):76-81. PMID: 15158549.
      Citations:    
    296. Gerth WC, Sarma S, Hu XH, Silberstein SD. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model. J Occup Environ Med. 2004 Jan; 46(1):48-54. PMID: 14724478.
      Citations:    
    297. Ashkenazi A, Silberstein SD. Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med. 2004; 55:505-18. PMID: 14746533.
      Citations:    
    298. Silberstein SD. Chronic migraine: diagnosis and management strategy. Rev Neurol Dis. 2004; 1(3):155-60. PMID: 16400273.
      Citations:    
    299. Evans RW, Lipton RB, Silberstein SD. The prevalence of migraine in neurologists. Neurology. 2003 Nov 11; 61(9):1271-2. PMID: 14610136.
      Citations:    
    300. Silberstein SD. Topiramate in migraine prevention. Expert Rev Neurother. 2003 Nov; 3(6):761-71. PMID: 19810879.
      Citations:    
    301. Blumenfeld AM, Binder W, Silberstein SD, Blitzer A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache. 2003 Sep; 43(8):884-91. PMID: 12940810.
      Citations:    
    302. Silberstein SD, Aoki KR. Botulinum toxin type A: myths, facts, and current research. Headache. 2003 Jul-Aug; 43 Suppl 1:S1. PMID: 12887387.
      Citations:    
    303. Silberstein SD. Neurotoxins in the neurobiology of pain. Headache. 2003 Jul-Aug; 43 Suppl 1:S2-8. PMID: 12887388.
      Citations:    
    304. Ashkenazi A, Silberstein SD. The evolving management of migraine. Curr Opin Neurol. 2003 Jun; 16(3):341-5. PMID: 12858071.
      Citations:    
    305. Silberstein SD, McKinstry RC. The death of idiopathic intracranial hypertension? Neurology. 2003 May 13; 60(9):1406-7. PMID: 12743219.
      Citations:    
    306. Silberstein SD. Analyses of cost-effectiveness of migraine therapies should consider multiple measures. J Manag Care Pharm. 2003 May-Jun; 9(3):279-80; author reply 280-1. PMID: 14613476.
      Citations:    
    307. Bigal ME, Lipton RB, Silberstein SD. Re: chronic daily headache in children and adolescents presenting to tertiary headache clinics. Headache. 2003 Apr; 43(4):419-21. PMID: 12656719.
      Citations:    
    308. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache. 2003 Mar; 43(3):171-8. PMID: 12603635.
      Citations:    
    309. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb; 43(2):144-66. PMID: 12558771.
      Citations:    
    310. Chatterton ML, Lofland JH, Shechter A, Curtice WS, Hu XH, Lenow J, Smullens SN, Nash DB, Silberstein SD. Reliability and validity of the migraine therapy assessment questionnaire. Headache. 2002 Nov-Dec; 42(10):1006-15. PMID: 12453032.
      Citations:    
    311. Silberstein SD, Welch KM. Painkiller headache. Neurology. 2002 Oct 8; 59(7):972-4. PMID: 12370449.
      Citations:    
    312. Silberstein SD, Massiou H, McCarroll KA, Lines CR. Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache. 2002 Oct; 42(9):917-23. PMID: 12390621.
      Citations:    
    313. Mendes PM, Silberstein SD, Young WB, Rozen TD, Paolone MF. Intravenous propofol in the treatment of refractory headache. Headache. 2002 Jul-Aug; 42(7):638-41. PMID: 12482216.
      Citations:    
    314. Silberstein SD, Liu D. Drug overuse and rebound headache. Curr Pain Headache Rep. 2002 Jun; 6(3):240-7. PMID: 12003696.
      Citations:    
    315. Silberstein SD, Peres MF. Hemicrania continua. Arch Neurol. 2002 Jun; 59(6):1029-30. PMID: 12056943.
      Citations:    
    316. Silberstein SD, Peres MF, Hopkins MM, Shechter AL, Young WB, Rozen TD. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache. 2002 Jun; 42(6):515-8. PMID: 12167140.
      Citations:    
    317. Peres MF, Silberstein SD. Hemicrania continua responds to cyclooxygenase-2 inhibitors. Headache. 2002 Jun; 42(6):530-1. PMID: 12167145.
      Citations:    
    318. Evans RW, Silberstein SD. Diagnostic testing for chronic daily headache. Headache. 2002 Jun; 42(6):556-9. PMID: 12167151.
      Citations:    
    319. Silberstein SD. Pharmacological profile and clinical characteristics of frovatriptan in the acute treatment of migraine: introduction. Headache. 2002 Apr; 42 Suppl 2:S45-6. PMID: 12028319.
      Citations:    
    320. Silberstein SD. Tricyclic antidepressant medication, stress management therapy, and their combination in the management of chronic tension-type headache. Curr Neurol Neurosci Rep. 2002 Mar; 2(2):105-7. PMID: 11898475.
      Citations:    
    321. Shechter A, Stewart WF, Silberstein SD, Lipton RB. Migraine and autonomic nervous system function: a population-based, case-control study. Neurology. 2002 Feb 12; 58(3):422-7. PMID: 11839842.
      Citations:    
    322. Siow HC, Young WB, Peres MF, Rozen TD, Silberstein SD. Hemiplegic cluster. Headache. 2002 Feb; 42(2):136-9. PMID: 12005289.
      Citations:    
    323. Dodick DW, Silberstein S, Dahlöf CG. Is there a preferred triptan? Headache. 2002 Jan; 42(1):1-7. PMID: 12005269.
      Citations:    
    324. Silberstein SD. Control of topiramate-induced paresthesias with supplemental potassium. Headache. 2002 Jan; 42(1):85. PMID: 12005283.
      Citations:    
    325. Silberstein SD. Clinical results of botulinum toxin type a treatment of migraine headache. Aesthet Surg J. 2002 Jan; 22(1):91-3. PMID: 19331960.
      Citations:    
    326. Silberstein SD. MIGRAINE AND PREGNANCY. J SOGC. 2000 Sep; 22(9):700-707. PMID: 12457199.
      Citations:    
    327. Silberstein SD. Migraine and women. Postgrad Med. 1995 Apr; 97(4):147-153. PMID: 29224452.
      Citations:    
    Silberstein's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (415)
    Explore
    _
    Co-Authors (28)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _